{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:17:27Z","timestamp":1648667847816},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clinthera.2016.12.015","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T14:15:35Z","timestamp":1485353735000},"page":"337-346","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study"],"prefix":"10.1016","volume":"39","author":[{"given":"Francois","family":"Bethoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeli","family":"Mayadev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Zackowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Blight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.12.015_bib1","first-page":"8","article-title":"A report: the definition and classification of cerebral palsy April 2006","volume":"109","author":"Rosenbaum","year":"2007","journal-title":"Dev Med Child Neurol Suppl"},{"key":"10.1016\/j.clinthera.2016.12.015_bib2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/jama.296.13.1602","article-title":"Clinical and MRI correlates of cerebral palsy: the European Cerebral Palsy Study","volume":"296","author":"Bax","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.12.015_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1017\/S0012162201","article-title":"Adults with cerebral palsy: a survey describing problems, needs, and resources, with special emphasis on locomotion","volume":"43","author":"Andersson","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.clinthera.2016.12.015_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1469-8749.2008.03250.x","article-title":"Walking function, pain, and fatigue in adults with cerebral palsy: a 7-year follow-up study","volume":"51","author":"Opheim","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.clinthera.2016.12.015_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12512","article-title":"Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis","volume":"1329","author":"Blight","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2016.12.015_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1756285613512712","article-title":"4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review","volume":"7","author":"Jensen","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2016.12.015_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.12.015_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2016.12.015_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7224\/1537-2073.2014-036","article-title":"Dalfampridine effects beyond walking speed in multiple sclerosis: results from the STEADY study","volume":"17","author":"Fjeldstad","year":"2015","journal-title":"Int J MS Care"},{"key":"10.1016\/j.clinthera.2016.12.015_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1352458515581436","article-title":"Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial","volume":"22","author":"Hupperts","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2016.12.015_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2015.06.008","article-title":"Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders","volume":"359","author":"Lo","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2016.12.015_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2340\/16501977-2033","article-title":"Dalfampridine in chronic sensorimotor deficits after ischemic stroke: a proof of concept study","volume":"47","author":"Simpson","year":"2015","journal-title":"J Rehab Med"},{"key":"10.1016\/j.clinthera.2016.12.015_bib13","first-page":"91","article-title":"Cerebral palsy: an overview","volume":"73","author":"Krigger","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2016.12.015_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1469-8749.2007.00542.x","article-title":"Evaluating interventions to improve gait in cerebral palsy: a meta-analysis of spatiotemporal measures","volume":"49","author":"Paul","year":"2007","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.clinthera.2016.12.015_bib15","unstructured":"Ampyra\u00ae [dalfampridine] extended release (ER) tablets prescribing information. Acorda Therapeutics, Inc, Ardsley, NY. December 2014."},{"key":"10.1016\/j.clinthera.2016.12.015_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.drudis.2008.03.026","article-title":"Failure is an option: learning from unsuccessful proof-of-concept trials","volume":"13","author":"Sch\u00e4fer","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2016.12.015_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fneur.2014.00258","article-title":"What are the best animal models for testing early intervention in cerebral palsy?","volume":"5","author":"Clowry","year":"2014","journal-title":"Front Neurol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817300012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817300012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T21:55:50Z","timestamp":1536098150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817300012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0149291817300012"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}